November 25, 2021
Takeda Pharmaceutical said on November 24 that the US FDA has granted approval for Livtencity (maribavir) for the treatment of patients with post-transplant cytomegalovirus (CMV) infection refractory to conventional antiviral therapies. The greenlight is based on data from a global...read more